Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston

Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) announced that CEO John P. Butler and CFO/CBO Erik Ostrowski will participate in one-on-one investor meetings at the Wells Fargo Healthcare Conference in Boston, held September 8–10, 2026. Management plans to discuss Akebia’s commercial kidney disease products and its pipeline of clinical-stage programs.

Market Context

AQST was up 2.71% pre-headline while its same-day headline also concerned investor conferences, prov...

Analysis

AQST was up 2.71% pre-headline while its same-day headline also concerned investor conferences, providing a relevant peer reference. AKBA's notice supplied scheduling information, while recent insider activity was Net Selling; company results remain the key watch.

Key Figures

Announcement date: September 01, 2026 Conference dates: September 8 10, 2026 Founded: 2007

3 metrics

Announcement date September 01, 2026 News announcement

Conference dates September 8 10, 2026 Wells Fargo Healthcare Conference in Boston

Founded 2007 Akebia Therapeutics

Historical Context

5 past events · Latest: Aug 05 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 05	Q2 earnings report	Negative	-26.0%	Revenue declined and the company posted a net loss; Vafseo growth partially offset weakness.
Aug 03	Inducement grants	Neutral	+0.8%	Two employees received inducement options covering 61,000 shares at a $1.32 exercise price.
Aug 03	Phase 2 trial initiation	Positive	-0.8%	Initiated an open-label Phase 2 basket trial of ebribafusp in rare kidney diseases.
Jul 29	Earnings date notice	Neutral	-0.8%	Announced the August 5 release date and 4:30 p.m. EDT conference call.
Jul 02	Inducement grants	Neutral	+4.8%	Three employees received inducement awards covering 125,600 shares at $1.14 per share.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historical reactions were mixed, including a -26.02% move after the Q2 earnings release and a -0.76% move after Phase 2 trial initiation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in one-on-one meetings at the Wells Fargo Healthcare Conference, which will take place in Boston, September 8 – 10, 2026.

During meetings, management will discuss its commercial products and its robust pipeline of clinical stage kidney disease programs.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com  

FAQ

What did Akebia Therapeutics (AKBA) announce about the 2026 Wells Fargo Healthcare Conference?

Akebia Therapeutics announced that senior management will hold one-on-one investor meetings at the 2026 Wells Fargo Healthcare Conference in Boston. According to Akebia, these meetings will focus on its commercial kidney disease products and clinical-stage pipeline programs, providing investors with an update on its business.

When and where is Akebia Therapeutics (AKBA) meeting investors during the 2026 Wells Fargo Healthcare Conference?

Akebia will participate in investor meetings at the Wells Fargo Healthcare Conference in Boston from September 8–10, 2026. According to Akebia, its CEO and CFO/CBO will attend these one-on-one sessions to discuss the company’s kidney disease portfolio and pipeline.

Which Akebia Therapeutics (AKBA) executives will attend the 2026 Wells Fargo Healthcare Conference?

Akebia stated that Chief Executive Officer John P. Butler and Chief Financial and Chief Business Officer Erik Ostrowski will attend. According to Akebia, they will participate in one-on-one investor meetings, highlighting the company’s commercial products and clinical-stage kidney disease programs during the Boston conference.

What topics will Akebia Therapeutics (AKBA) discuss with investors at the 2026 Wells Fargo Healthcare Conference?

Akebia plans to discuss its commercial products and its pipeline of clinical-stage kidney disease programs during the one-on-one meetings. According to Akebia, these discussions aim to provide investors deeper insight into its current kidney disease portfolio and ongoing development initiatives.

How can investors learn more about Akebia Therapeutics (AKBA) around the 2026 Wells Fargo Healthcare Conference?

Investors can learn more by engaging in scheduled one-on-one meetings at the Wells Fargo Healthcare Conference and visiting Akebia’s website. According to Akebia, its website at www.akebia.com offers additional background, though it does not form part of the conference announcement.